Impact of microscopic extrathyroidal extension on differentiated thyroid cancer post-surgical risk of recurrence: a retrospective analysis.
Differentiated thyroid cancer
Microscopic extrathyroidal extension
Predictive performance
Recurrence risk
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
29
09
2022
accepted:
12
03
2023
medline:
25
9
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
In the last edition of the American Joint Committee on Cancer (AJCC) staging system, differentiated thyroid cancers (DTC) showing microscopic extrathyroidal extension (mETE) are considered comparable to intrathyroidal cancers for their clinical behavior and prognosis. The aim of the study is to evaluate the impact of this updated assessment of T, when applied to the postoperative recurrence risk stratification, according to the American Thyroid Association Guidelines (ATA-RR). One-hundred DTC patients who underwent total thyroidectomy were retrospectively evaluated. The downstaging of mETE was introduced in the definition of T, and the updated classification defined as modified ATA-RR (ATAm-RR). For each patient, post-surgical basal and stimulated thyroglobulin (Tg) levels, neck ultrasound (US) and post-ablative 131-I whole body scan (WBS) reports were considered. The predictive performance (PP) of disease recurrence was calculated both for each single parameter, as well as for all of them. According to ATAm-RR classification, 19/100 patients (19%) were downstaged. ATA-RR proved a significant PP for disease recurrence (DR) (sensitivity 75.0%, specificity 63.0%, p = 0.023). However, ATAm-RR performed slightly better due to an increased specificity (sensitivity 75.0%, specificity 83.7%, p < 0.001). For both classifications, the PP was optimal when all the above-mentioned predictive parameters were considered. Our results suggest that the new assessment of T considering mETE resulted in a downgrading of ATA-RR class in a significant number of patients. This provides a better PP for disease recurrence, and the best PP was obtained when considering the whole predictive variables together.
Identifiants
pubmed: 36976482
doi: 10.1007/s40618-023-02070-y
pii: 10.1007/s40618-023-02070-y
pmc: PMC10514175
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2157-2164Informations de copyright
© 2023. The Author(s).
Références
Front Endocrinol (Lausanne). 2019 Jan 24;10:10
pubmed: 30733707
Thyroid. 2016 Nov;26(11):1541-1552
pubmed: 27571228
Clin Nucl Med. 2012 Jun;37(6):545-9
pubmed: 22614184
World J Surg. 2006 May;30(5):780-6
pubmed: 16411013
Oral Oncol. 2017 Sep;72:183-187
pubmed: 28222967
Surgery. 2021 Jan;169(1):2-6
pubmed: 32682508
J Clin Endocrinol Metab. 2014 Feb;99(2):440-7
pubmed: 24285679
Chin Med J (Engl). 2015 Apr 20;128(8):1058-64
pubmed: 25881600
J Clin Endocrinol Metab. 2019 Sep 1;104(9):4087-4100
pubmed: 30874735
Thyroid. 2019 Jan;29(1):7-26
pubmed: 30484394
J Clin Endocrinol Metab. 2016 Jul;101(7):2692-700
pubmed: 27023446
Thyroid. 2017 Feb;27(2):174-181
pubmed: 27750028
Thyroid. 2020 Jun;30(6):871-877
pubmed: 31524071
Nucl Med Rev Cent East Eur. 2014;17(1):3-6
pubmed: 24610645
Ther Adv Endocrinol Metab. 2020 May 19;11:2042018820921019
pubmed: 32489582
Thyroid. 2020 May;30(5):713-719
pubmed: 31973653
Eur J Cancer (1965). 1979 Aug;15(8):1033-41
pubmed: 510341
Br J Surg. 2020 May;107(6):687-694
pubmed: 32026467
Acta Clin Croat. 2018 Sep;57(3):518-527
pubmed: 31168186
Ann Surg Oncol. 2008 May;15(5):1518-22
pubmed: 18324441
Surgery. 2008 Dec;144(6):942-7; discussion 947-8
pubmed: 19041001
Nat Rev Endocrinol. 2013 Mar;9(3):178-84
pubmed: 23358352
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32597947
BJS Open. 2019 Jun 28;3(5):623-628
pubmed: 31592514
Endocr Relat Cancer. 2004 Sep;11(3):571-9
pubmed: 15369456
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2199-2206
pubmed: 29672723
J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63
pubmed: 22639291
Int J Mol Sci. 2017 Jun 17;18(6):
pubmed: 28629126
J Endocrinol Invest. 2018 Jul;41(7):849-876
pubmed: 29729004
Oral Oncol. 2017 Aug;71:81-86
pubmed: 28688696
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Endocr Relat Cancer. 2017 May;24(5):221-226
pubmed: 28249964
Ann Surg Oncol. 2011 Jul;18(7):1916-23
pubmed: 21267788
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S728-33
pubmed: 26077913
PLoS One. 2019 Jun 14;14(6):e0218171
pubmed: 31199822
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503148
Sci Rep. 2021 Jul 21;11(1):14908
pubmed: 34290341
Ann Surg. 2020 Apr;271(4):765-773
pubmed: 30339630
Thyroid. 2017 Jun;27(6):751-756
pubmed: 28463585
Eur J Endocrinol. 2013 Mar 15;168(4):549-56
pubmed: 23337385